SLC5A2 and type 2 diabetes mellitus: The 2022 AHA/ACC/HFSA guidelines carry a Class IA recommendation for SGLT-2 inhibitors in patients with symptomatic chronic HFrEF to reduce hospitalizations and mortality regardless of type 2 diabetes mellitus status [7].